2. NF-κB MAPK/ERK Pathway Apoptosis
  3. NF-κB p38 MAPK Bcl-2 Family Caspase Apoptosis
  4. DNH28

DNH28 is a potent NF-κB and MAPK inhibitor with an IC50 of 0.93 μM against HepG2 cells. DNH28 promotes apoptosis by down-regulating the expression of Bcl-2, up-regulating the expression of BAX and Cleaved-caspase-3. DNH28 blocks the cell cycle and inhibits migration. DNH28 can be used for the study of hepatocellular carcinoma (HCC).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

DNH28

DNH28 Chemische Struktur

Größe Verfügbarkeit
50 mg   Angebot einholen  
100 mg   Angebot einholen  
250 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

DNH28 Related Antibodies

Top Publications Citing Use of Products

Alle NF-κB Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Alle p38 MAPK Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen
p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

Alle Caspase Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biologische Aktivität

  • Reinheit & Dokumentation

  • Verweise

  • Kundenbewertung

Beschreibung

DNH28 is a potent NF-κB and MAPK inhibitor with an IC50 of 0.93 μM against HepG2 cells. DNH28 promotes apoptosis by down-regulating the expression of Bcl-2, up-regulating the expression of BAX and Cleaved-caspase-3. DNH28 blocks the cell cycle and inhibits migration. DNH28 can be used for the study of hepatocellular carcinoma (HCC)[1].

IC50 & Target[1]

Caspase 3

 

Bax

 

Bcl-2

 

NF-κB

 

In Vitro

DNH28 (Compound 28) exhibits lower toxicity toward THLE-3 cells (IC50 = 18.16 μM)[1].
DNH28 (0.46-1.84 μM, 24 h) inhibits HepG2 cells proliferation by inducing apoptosis and dose-dependently inhibits HepG2 cells in the G2/M phase[1].
DNH28 (0.46-1.84 μM, 24 h) inhibits HepG2 cell migration dose-dependently, and it completely inhibits the migration ability at a concentration of 1.84 μM[1].
DNH28 (1.84 μM, 24 h) effectively inhibits the nuclear translocation of p65 induced by TNF-α[1].
DNH28 (0.46-1.84 μM, 24 h) exerts anti-HCC effects by inhibiting the activation of NF-κB and MAPK signaling pathways[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DNH28 Related Antibodies

Apoptosis Analysis[1]

Cell Line: HepG2 cells
Concentration: 0.46, 0.92 and 1.84 μM
Incubation Time: 24 h
Result: Induced apoptosis dose-dependently.
Reached 45.90% of apoptotic cells at 1.84 μM (compared with 14.57% in the control group).

Cell Cycle Analysis[1]

Cell Line: HepG2 cells
Concentration: 0.46, 0.92 and 1.84 μM
Incubation Time: 24 h
Result: Reached 76.22% G2/M phase ratio at 1.84 μM.

Cell Migration Assay [1]

Cell Line: HepG2 cells
Concentration: 0.46, 0.92 and 1.84 μM
Incubation Time: 24 h
Result: Partially suppressed cell migration, whereas at 1.84 μM, the scratch width remained unchanged.

RT-PCR[1]

Cell Line: HepG2 cells
Concentration: 0.46, 0.92 and 1.84 μM
Incubation Time: 24 h
Result: Increased the expression of pro-apoptotic mRNA levels BAX and C-caspase-3.
Reduced the expression of the anti-apoptotic mRNA levels of BCL-2.

Western Blot Analysis[1]

Cell Line: HepG2 cells
Concentration: 0.46, 0.92 and 1.84 μM
Incubation Time: 24 h
Result: Exhibited dose-dependent inhibition of the phosphorylation of p65, IκB-α, p38 and ERK.
Significantly down-regulated the activation of the NF-κB and MAPK signaling pathways
Molekulargewicht

436.90

Formel

C23H24ClF3N2O
SMILES

CCN1CCN(C2=CC(CC/C(C3=O)=C\C4=CC=C(F)C(F)=C4F)=C3C=C2)CC1.Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DNH28 Related Classifications

  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DNH28DNH 28DNH-28NF-κBp38 MAPKBcl-2 FamilyCaspaseApoptosisNuclear factor-κBNuclear factor-kappaBAnti-HCCNF-κB inhibitorMAPK inhibitorNF-κB pathwayMAPK pathwayHepG2 cellsInhibitorinhibitorinhibit

Ihre kürzlich angesehenen Produkte:

Online-Anfrage

Your information is safe with us. * Required Fields.

Produktname

  

Requested Quantity *

Name des Antragstellers *

 

Anrede

E-Mail-Addresse *

 

Telefonnummer *

Department

 

Name der Organisation *

City

Bundesland

Country or Region *

      

Bemerkungen

Massenanfrage

Inquiry Information

Produktname:
DNH28
Art. -Nr.:
HY-175037
Menge:
MCE Japan Authorized Agent:

Kundenbewertung

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Produktname

  

Lot #

Name des Antragstellers *

 

E-Mail-Addresse *

Telefonnummer

 

Department *

Name der Organisation *

 

Country or Region *

Bemerkungen

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.